The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 3 March 2026•Updated 3 March 2026•

1 min read

Esperion Therapeutics (ESPR) Acquires Private Corstasis to Expand Cardiovascular and Renal Portfolio

Key Facts

1Esperion Therapeutics announced a definitive agreement to acquire Corstasis Therapeutics.

3 months ago

Version History

Version 13 months ago

What changed: Added the ticker (ESPR), clarified Corstasis's status as a private company, specified the drug's chemical composition as bumetanide, and expanded the therapeutic scope to include hepatic and renal diseases.

Esperion Therapeutics (NASDAQ: ESPR) has announced a definitive agreement to acquire the private firm Corstasis Therapeutics, a strategic move aimed at strengthening its position in the cardiovascular and renal treatment markets. The acquisition features Enbumyst™, a bumetanide-based nasal spray that stands as the first FDA-approved loop diuretic of its kind for edema management. Notably, the drug's application scope has been expanded to include edema associated with hepatic and renal diseases, in addition to congestive heart failure. Esperion expects the deal to accelerate its revenue growth by more than 10% by leveraging its established commercial infrastructure and specialized sales network. Analysts view the acquisition of an FDA-approved product with multiple indications as a bullish signal, providing immediate portfolio expansion without typical clinical trial risks. This integration underscores Esperion's commitment to driving growth through innovative treatments for complex chronic conditions.